The agency’s decision expands the use of Zepbound and could potentially pave the way for Eli Lilly to gain broader insurance ...

He now oversees Eli Lilly’s pipeline of incretin medications, including its blockbuster weight-loss drug Zepbound. Now, recent studies and clinical trials have found that these drugs also have ...

Eli Lilly is seeking to end a lawsuit filed by a pharmacy trade group against the Food and Drug Administration (FDA) by joining as a defendant, stating it wants to end the “entitlement” some ...

Eli Lilly's obesity drug Mounjaro will be available through Britain's state health system for some patients from March, after ...

The mega-blockbuster weight loss GLP-1 drug is now also approved to treat obstructive sleep apnea in adults with obesity, in ...

The Food and Drug ... calorie diet and increased physical activity, the FDA noted in a release. An estimated 80 million patients in the U.S. experience the disease, according to Eli Lilly.

offering new hope with its groundbreaking treatment for weight management. Eli Lilly's Zepbound drug has the potential to dominate the global obesity market with its superior efficacy and ...

Eli Lilly moves to defend FDA's tirzepatide shortage resolution amid criticism over supply issues and compounding pharmacy ...

The stock of the pharmaceutical company, Lupin is quoting higher for the sixth straight trading day; it has rallied 10 per ...

The FDA approved Eli Lilly's Zepbound as the first drug for obesity-linked moderate-to-severe sleep apnea, potentially transforming treatment options for 80 million Americans.

The compounding groups filed a complaint in October 2024 alleging that removing the drug from the shortage ... Why It Matters: In a motion filed on New Year, Eli Lilly said it seeks to intervene ...